| 1. |
- Chakera, Annette H., et al.
(författare)
-
EANM-EORTC general recommendations for sentinel node diagnostics in melanoma
- 2009
-
Ingår i: European Journal of Nuclear Medicine and Molecular Imaging. - : Springer Science and Business Media LLC. - 1619-7070 .- 1619-7089. ; 36:10, s. 1713-1742
-
Forskningsöversikt (refereegranskat)abstract
- The accurate diagnosis of a sentinel node in melanoma includes a sequence of procedures from different medical specialities (nuclear medicine, surgery, oncology, and pathology). The items covered are presented in 11 sections and a reference list: (1) definition of a sentinel node, (2) clinical indications, (3) radiopharmaceuticals and activity injected, (4) dosimetry, (5) injection technique, (6) image acquisition and interpretation, (7) report and display, ( 8) use of dye, ( 9) gamma probe detection, (10) surgical techniques in sentinel node biopsy, and (11) pathological evaluation of melanoma-draining sentinel lymph nodes. If specific recommendations given cannot be based on evidence from original, scientific studies, referral is given to "general consensus" and similar expressions. The recommendations are designed to assist in the practice of referral to, performance, interpretation and reporting of all steps of the sentinel node procedure in the hope of setting state-of-the-art standards for good-quality evaluation of possible spread to the lymphatic system in intermediate-to-high risk melanoma without clinical signs of dissemination.
|
|
| 2. |
- Chakera, Annette H., et al.
(författare)
-
Sentinel node imaging
- 2006
-
Ingår i: Current Medical Imaging Reviews. - : Bentham Science Publishers Ltd.. - 1875-6603 .- 1573-4056. ; 2:3, s. 341-346
-
Forskningsöversikt (refereegranskat)abstract
- Breast cancer and melanoma metastasize predominantly via the lymphatic route. It has long been known that invasion into one or a few nodes draining the primary tumour, the sentinel nodes (SN), is the most important, early sign of dissemination. If no malignant cells are detected in the SN, dissemination is unlikely to be expected. For the last 10 years SN biopsy has become an important tool in staging cancers. Two kinds of tracers are used for SN detection: The blue dye, injected during operation, and radioactively labelled colloid, injected before operation. The lymphatic drainage can then be mapped by following the blue dye by visual inspection during the operation, and with gamma camera imaging before and probe detection during the operation. The variations in the tracers used, and the injection and imaging techniques are discussed. The pathologic examination has also undergone a rapid evolution with more detailed analysis including immunohistochemistry. The use of the SN technique has quickly spread worldwide for melanoma and breast cancer but is also being tested in several other cancers. Reports on the influence on morbidity and mortality reduction are becoming increasingly convincing. The near future of SN examination is finally briefly outlined.
|
|
